We examined the trends in use of imaging as well as costs associated with imaging within 12 months from diagnosis of bladder cancer. A total of 36,855 patients aged 66 years or older diagnosed with clinical stage TI-IV, N0M0 bladder cancer from 2004 to 2011 were analyzed. In total, 24,240 (65.8%) patients received one of these three imaging modalities within 12 months after bladder cancer diagnosis: 1,291 (3.5%) PET/CT, 1,495 (4.1%) MRI, and 21,454 (58.2%) CT. Independent of clinical stage, there was marked increase in use of PET/CT throughout the study period (2011 v 2004: OR 17.55, 95% CI = 10.14-30.38, P<0.001). We also observed a greater use of PET/CT among female patients, residents in West region, patients diagnosed with hydronephrosis or high grade tumor, and patients who underwent surgery, chemotherapy, or radiation therapy.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
In summary, we assessed trends in use of PET/CT, MRI, and CT among bladder cancer patients. Our study revealed a significant shift in the type of imaging modality performed during the study period. Specifically, we observed marked 16-fold increased use of PET/CT regardless of clinical stage. This rapid adoption of PET/CT translated into excess national spending of approximately $11 million. These findings have important implications regarding health policy decision-making and the need for improved value-based bladder cancer care.
Written by: Stephen B. Williams, MD, The University of Texas Medical Branch
Read the Abstract